patient

UST Secures $2 Billion in Deals with Leading Healthcare Companies, Accelerating AI-Driven Innovation and Personalized Patient ExperiencesUST Secures $2 Billion in Deals with Leading Healthcare Companies, Accelerating AI-Driven Innovation and Personalized Patient Experiences

UST Secures $2 Billion in Deals with Leading Healthcare Companies, Accelerating AI-Driven Innovation and Personalized Patient Experiences

P artnerships with leading healthcare enterprises expand UST's role in transforming the healthcare landscape at scale BENGALURU, India, Oct. 7,…

2 days ago
Mactores Earns AWS Healthcare Competency Status, Enabling HIPAA-Compliant AI Solutions for Improved Patient Outcomes and Operational ExcellenceMactores Earns AWS Healthcare Competency Status, Enabling HIPAA-Compliant AI Solutions for Improved Patient Outcomes and Operational Excellence

Mactores Earns AWS Healthcare Competency Status, Enabling HIPAA-Compliant AI Solutions for Improved Patient Outcomes and Operational Excellence

Mactores has earned AWS Healthcare Competency, validating its expertise in automation-first, HIPAA-compliant solutions. By modernizing data foundations and accelerating AI…

4 days ago
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal AdenocarcinomaRadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma

Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs…

4 weeks ago
Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience ForwardMedidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward

Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by…

1 month ago
FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITISFIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…

1 month ago
New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient SubgroupsNew REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…

1 month ago
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomesSOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a…

2 months ago
Floe Health Launches to Power Intelligence at Every Patient TouchpointFloe Health Launches to Power Intelligence at Every Patient Touchpoint

Floe Health Launches to Power Intelligence at Every Patient Touchpoint

July 28, 2025 12:04 ET  | Source: Floe Health San Francisco, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Floe Health,…

2 months ago
NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting TherapyNKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 10, 2025 16:30 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen…

3 months ago
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic DermatitisInmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

July 01, 2025 09:00 ET  | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…

3 months ago
Show more Posts